Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
 Back to Profile

Kian Behbakht

Concepts (451)

Concepts are derived automatically from a person's publications.

Cloud
Categories
Timeline
Details
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Ovarian Neoplasms
44
2025
490
5.550
 Why?
Poly(ADP-ribose) Polymerase Inhibitors
8
2024
90
1.320
 Why?
Peritoneal Neoplasms
7
2024
87
1.130
 Why?
Endometrial Neoplasms
10
2019
164
1.060
 Why?
Drug Resistance, Neoplasm
16
2024
750
1.000
 Why?
Antineoplastic Combined Chemotherapy Protocols
9
2020
1573
0.960
 Why?
Genital Neoplasms, Female
6
2020
81
0.940
 Why?
Uterine Cervical Neoplasms
8
2017
235
0.930
 Why?
Cystadenocarcinoma, Serous
6
2024
68
0.850
 Why?
Hysterectomy
4
2018
120
0.770
 Why?
Antineoplastic Agents
10
2023
2060
0.750
 Why?
Fallopian Tube Neoplasms
6
2024
15
0.730
 Why?
TNF-Related Apoptosis-Inducing Ligand
5
2017
43
0.670
 Why?
Biomarkers, Tumor
8
2019
1185
0.630
 Why?
Gelatin
2
2016
40
0.620
 Why?
Neoplasms, Glandular and Epithelial
3
2015
35
0.600
 Why?
Thrombin
2
2016
142
0.590
 Why?
Models, Economic
1
2018
55
0.590
 Why?
Claudin-4
4
2025
15
0.570
 Why?
Hyperthermia, Induced
1
2018
109
0.560
 Why?
Pelvic Infection
1
2016
4
0.530
 Why?
Female
84
2025
68510
0.520
 Why?
Cell Line, Tumor
20
2025
3184
0.520
 Why?
Homeodomain Proteins
3
2012
493
0.520
 Why?
Tissue Adhesives
1
2016
18
0.520
 Why?
Neoplastic Cells, Circulating
2
2017
70
0.490
 Why?
Cost-Benefit Analysis
1
2018
582
0.490
 Why?
Women
1
2015
52
0.460
 Why?
Sirolimus
2
2016
189
0.460
 Why?
Neoplasm Recurrence, Local
6
2019
963
0.450
 Why?
Vagina
6
2016
176
0.420
 Why?
Health Knowledge, Attitudes, Practice
2
2015
1275
0.390
 Why?
Antibodies, Neoplasm
1
2012
35
0.390
 Why?
Neoplasm Staging
15
2024
1293
0.380
 Why?
Humans
88
2025
129116
0.380
 Why?
Middle Aged
47
2024
31074
0.370
 Why?
Cisplatin
2
2015
298
0.370
 Why?
Histone-Lysine N-Methyltransferase
2
2024
125
0.350
 Why?
Aged
35
2024
22083
0.330
 Why?
Neoadjuvant Therapy
4
2020
381
0.330
 Why?
Robotic Surgical Procedures
3
2016
110
0.330
 Why?
Pelvic Exenteration
1
2009
11
0.330
 Why?
Apoptosis
8
2019
2438
0.330
 Why?
Leiomyosarcoma
3
2020
27
0.320
 Why?
Uterine Neoplasms
4
2019
102
0.320
 Why?
Paclitaxel
3
2019
215
0.320
 Why?
Phthalazines
2
2019
40
0.320
 Why?
Cytoreduction Surgical Procedures
2
2020
61
0.320
 Why?
Receptors, TNF-Related Apoptosis-Inducing Ligand
3
2017
29
0.320
 Why?
Aged, 80 and over
17
2020
7064
0.310
 Why?
Pyrimidines
3
2019
445
0.310
 Why?
Health Personnel
1
2015
649
0.310
 Why?
Tumor Microenvironment
2
2024
622
0.310
 Why?
Carcinoma, Endometrioid
3
2019
47
0.300
 Why?
Chemotherapy, Adjuvant
2
2020
376
0.300
 Why?
Caffeine
1
2008
62
0.290
 Why?
Carbazoles
1
2008
84
0.290
 Why?
Azepines
2
2019
88
0.290
 Why?
Clinical Competence
1
2015
1021
0.290
 Why?
Papanicolaou Test
2
2004
43
0.280
 Why?
Vaginal Smears
2
2004
57
0.280
 Why?
Piperazines
2
2019
337
0.270
 Why?
Protein Kinase C
1
2008
253
0.270
 Why?
Postoperative Complications
6
2020
2496
0.270
 Why?
Gene Expression Regulation, Neoplastic
7
2025
1353
0.260
 Why?
Adult
29
2020
35510
0.250
 Why?
Hemostasis, Surgical
2
2016
19
0.250
 Why?
Laparotomy
2
2015
109
0.230
 Why?
Adenocarcinoma
4
2015
889
0.230
 Why?
Urban Health
1
2004
79
0.230
 Why?
Genomic Instability
1
2025
47
0.230
 Why?
Disease-Free Survival
7
2017
656
0.230
 Why?
Fallopian Tubes
1
2024
31
0.220
 Why?
Histocompatibility Antigens
2
2024
107
0.210
 Why?
Prognosis
9
2024
3788
0.210
 Why?
Pyrazoles
2
2020
405
0.210
 Why?
Genetic Therapy
2
2014
293
0.210
 Why?
Uterine Cervical Dysplasia
2
2003
43
0.200
 Why?
Adenocarcinoma, Clear Cell
2
2021
14
0.200
 Why?
Neoplasm Grading
5
2024
284
0.190
 Why?
Leiomyoma
2
2019
74
0.190
 Why?
Hospitals, Public
1
2001
26
0.180
 Why?
Healthcare Disparities
2
2018
581
0.180
 Why?
BRCA2 Protein
3
2019
53
0.180
 Why?
Piperidines
2
2019
190
0.180
 Why?
Hospitals, University
1
2001
176
0.180
 Why?
Vulvar Neoplasms
1
2020
11
0.180
 Why?
Cervix Uteri
3
2011
51
0.170
 Why?
Treatment Outcome
11
2020
10226
0.170
 Why?
Epoxy Compounds
1
2020
32
0.170
 Why?
Mutation
5
2019
3700
0.170
 Why?
Carnitine O-Palmitoyltransferase
1
2020
45
0.170
 Why?
Rad51 Recombinase
1
2019
12
0.170
 Why?
Enoxaparin
1
2020
59
0.160
 Why?
Cell Movement
2
2016
939
0.160
 Why?
Up-Regulation
2
2020
828
0.160
 Why?
Vaccines, Conjugate
1
2019
63
0.160
 Why?
Receptors, Adiponectin
1
2019
19
0.160
 Why?
Neoplasms
4
2017
2475
0.160
 Why?
Poly(ADP-ribose) Polymerases
1
2019
87
0.160
 Why?
Interleukin-12
2
2014
120
0.150
 Why?
Sequence Analysis, RNA
2
2019
428
0.150
 Why?
CD8-Positive T-Lymphocytes
1
2024
847
0.150
 Why?
Pyridones
1
2020
160
0.150
 Why?
Patient Acceptance of Health Care
1
2004
767
0.150
 Why?
Lymph Node Excision
2
2020
165
0.150
 Why?
Adjuvants, Immunologic
1
2019
221
0.150
 Why?
Cancer Vaccines
1
2019
165
0.150
 Why?
Cost Savings
1
2018
79
0.150
 Why?
Sarcoma
1
2020
177
0.150
 Why?
Ovariectomy
2
2015
139
0.150
 Why?
Oncologists
1
2018
37
0.150
 Why?
Cell Growth Processes
2
2008
52
0.150
 Why?
Dose-Response Relationship, Drug
4
2008
1945
0.140
 Why?
Pregnancy Complications, Infectious
1
2002
364
0.140
 Why?
Breast Neoplasms
4
2019
2150
0.140
 Why?
Aurora Kinase A
1
2017
55
0.140
 Why?
Antineoplastic Agents, Phytogenic
1
2019
186
0.140
 Why?
Leukocyte Common Antigens
1
2017
81
0.140
 Why?
beta Catenin
1
2019
219
0.140
 Why?
Anion Transport Proteins
1
2017
8
0.140
 Why?
Fatty Acids
1
2020
415
0.140
 Why?
Survival Rate
5
2020
1875
0.140
 Why?
Salpingectomy
2
2015
13
0.140
 Why?
Sexual Dysfunctions, Psychological
1
2017
34
0.130
 Why?
Gestational Trophoblastic Disease
1
2016
5
0.130
 Why?
Curettage
1
2016
9
0.130
 Why?
Animals
13
2024
34600
0.130
 Why?
Keratins
1
2017
175
0.130
 Why?
Megestrol Acetate
1
2016
2
0.130
 Why?
Carcinoma, Neuroendocrine
1
2016
32
0.130
 Why?
Sexual Dysfunction, Physiological
1
2017
67
0.130
 Why?
Risk Factors
6
2016
9767
0.130
 Why?
Minority Groups
1
2018
252
0.130
 Why?
Venous Thromboembolism
1
2020
275
0.130
 Why?
Neoplasms, Squamous Cell
1
1996
4
0.130
 Why?
Colony Count, Microbial
1
2016
116
0.130
 Why?
Standard of Care
1
2016
71
0.130
 Why?
Medroxyprogesterone Acetate
1
2015
35
0.130
 Why?
Adenoviridae
1
1996
190
0.130
 Why?
Brachytherapy
1
2016
103
0.130
 Why?
Gynecology
1
2018
175
0.130
 Why?
Cell Survival
4
2025
1077
0.120
 Why?
Gene Expression Profiling
2
2019
1689
0.120
 Why?
Anticoagulants
1
2020
614
0.120
 Why?
Keratin-5
1
2015
49
0.120
 Why?
Molecular Targeted Therapy
1
2018
387
0.120
 Why?
Reverse Transcriptase Polymerase Chain Reaction
1
2017
940
0.120
 Why?
Tretinoin
1
1996
128
0.120
 Why?
Tamoxifen
1
2016
200
0.120
 Why?
Chemoradiotherapy
1
2016
209
0.120
 Why?
Immunohistochemistry
3
2016
1671
0.120
 Why?
Mice
9
2024
16644
0.120
 Why?
Combined Modality Therapy
4
2020
1209
0.120
 Why?
Antineoplastic Agents, Hormonal
1
2015
161
0.120
 Why?
CA-125 Antigen
2
2008
15
0.120
 Why?
Abdominal Abscess
1
2014
26
0.110
 Why?
Surgeons
1
2018
277
0.110
 Why?
Mice, SCID
2
2012
347
0.110
 Why?
Kaplan-Meier Estimate
4
2020
864
0.110
 Why?
Immunotherapy
1
2018
588
0.110
 Why?
Lipid Metabolism
1
2017
493
0.110
 Why?
Reoperation
1
2016
560
0.110
 Why?
Endometrium
1
2014
61
0.110
 Why?
Glycoproteins
1
2015
337
0.110
 Why?
Cell Cycle
2
2025
581
0.110
 Why?
Cytokines
1
2002
1987
0.110
 Why?
Quality of Health Care
1
2018
608
0.110
 Why?
Interpersonal Relations
1
2017
387
0.110
 Why?
Transforming Growth Factor beta
1
1996
449
0.110
 Why?
Proto-Oncogene Proteins c-akt
2
2016
421
0.110
 Why?
Pelvic Neoplasms
1
2013
19
0.100
 Why?
Models, Biological
3
2019
1695
0.100
 Why?
Antigens, CD
1
2015
483
0.100
 Why?
Young Adult
5
2020
12389
0.100
 Why?
Genes, Tumor Suppressor
3
1998
86
0.100
 Why?
Plasmids
1
2014
357
0.100
 Why?
RNA, Messenger
2
2012
2676
0.100
 Why?
Gardnerella vaginalis
2
2002
4
0.100
 Why?
Escherichia coli
1
2016
771
0.100
 Why?
Antibody Specificity
1
2012
182
0.090
 Why?
Cell Division
2
2008
779
0.090
 Why?
Endocrine Gland Neoplasms
1
2011
1
0.090
 Why?
Transplantation, Heterologous
1
2012
187
0.090
 Why?
Neoplastic Stem Cells
1
2015
386
0.090
 Why?
RNA, Small Interfering
3
2020
571
0.090
 Why?
Cyclin D1
1
2011
63
0.090
 Why?
Drug Synergism
2
2011
358
0.090
 Why?
Proteasome Inhibitors
1
2011
44
0.090
 Why?
MicroRNAs
1
2017
677
0.090
 Why?
Adenocarcinoma, Mucinous
1
2011
75
0.090
 Why?
DNA
1
2017
1392
0.090
 Why?
Peptides
1
2015
911
0.090
 Why?
Transfection
2
2007
896
0.090
 Why?
Cell Proliferation
4
2019
2347
0.080
 Why?
Cadherins
1
2011
186
0.080
 Why?
Neoplasm Invasiveness
3
2016
480
0.080
 Why?
Lymphoma
1
2011
194
0.080
 Why?
Inflammation
1
2020
2668
0.080
 Why?
Age Factors
5
2016
3120
0.080
 Why?
Skin Transplantation
1
2009
88
0.080
 Why?
Anastomosis, Surgical
1
2009
150
0.080
 Why?
Adaptor Proteins, Signal Transducing
1
2011
391
0.080
 Why?
Adolescent
5
2020
20301
0.080
 Why?
Papillomaviridae
2
2002
113
0.080
 Why?
Urokinase-Type Plasminogen Activator
1
2008
29
0.080
 Why?
G2 Phase
1
2008
36
0.080
 Why?
TOR Serine-Threonine Kinases
1
2011
380
0.080
 Why?
Radiation-Protective Agents
1
2008
27
0.070
 Why?
Rectum
1
2009
169
0.070
 Why?
Case-Control Studies
4
2019
3342
0.070
 Why?
Models, Statistical
1
2011
626
0.070
 Why?
Heterografts
2
2019
129
0.070
 Why?
Genes, BRCA1
2
1998
32
0.070
 Why?
Class I Phosphatidylinositol 3-Kinases
2
2019
81
0.070
 Why?
Microsatellite Instability
2
2019
37
0.070
 Why?
Urinary Bladder
1
2009
175
0.070
 Why?
Cell Culture Techniques
2
2020
346
0.070
 Why?
Xenograft Model Antitumor Assays
2
2020
813
0.070
 Why?
Cysteine
1
2008
188
0.070
 Why?
Tumor Suppressor Protein p53
3
2019
508
0.070
 Why?
Gynecologic Surgical Procedures
2
2020
56
0.070
 Why?
PTEN Phosphohydrolase
2
2019
157
0.070
 Why?
Double-Blind Method
3
2019
1865
0.060
 Why?
Models, Animal
1
2008
367
0.060
 Why?
Adenosarcoma
2
2005
2
0.060
 Why?
Proportional Hazards Models
3
2020
1210
0.060
 Why?
Retrospective Studies
6
2020
14571
0.060
 Why?
Follow-Up Studies
4
2020
4915
0.060
 Why?
Signal Transduction
4
2012
4838
0.060
 Why?
Length of Stay
3
2015
1123
0.060
 Why?
Polymerase Chain Reaction
4
2002
1021
0.060
 Why?
Indazoles
2
2019
66
0.060
 Why?
Colposcopy
2
2003
16
0.060
 Why?
Intestinal Neoplasms
1
2005
28
0.060
 Why?
Ovary
1
2007
214
0.060
 Why?
Cell Count
2
2015
314
0.060
 Why?
Germ-Line Mutation
2
1996
138
0.060
 Why?
Neoplasm Proteins
3
1998
421
0.060
 Why?
United States
5
2022
13938
0.060
 Why?
Ultraviolet Rays
1
2008
384
0.060
 Why?
Sexual Behavior
1
2009
483
0.060
 Why?
Chicago
1
2004
58
0.060
 Why?
Disease Progression
3
2019
2613
0.060
 Why?
Tumor Cells, Cultured
2
1996
930
0.060
 Why?
Peptide Fragments
1
2008
686
0.060
 Why?
Antioxidants
1
2008
543
0.060
 Why?
Blood Loss, Surgical
2
2015
91
0.060
 Why?
Transcription Factors
4
2011
1632
0.060
 Why?
Survival Analysis
4
2020
1265
0.050
 Why?
Activating Transcription Factor 6
1
2023
17
0.050
 Why?
Receptors, Estrogen
2
2015
429
0.050
 Why?
Transcription Factor AP-1
1
2023
85
0.050
 Why?
X-ray Repair Cross Complementing Protein 1
1
2022
14
0.050
 Why?
Neoplasm Metastasis
2
2015
616
0.050
 Why?
Medical Oncology
1
2024
274
0.050
 Why?
Vaginal Neoplasms
1
2001
12
0.050
 Why?
Trichomonas vaginalis
1
2002
13
0.050
 Why?
Risk Assessment
3
2016
3260
0.050
 Why?
Phosphatidylinositol 3-Kinases
2
2016
357
0.050
 Why?
Gene Expression
1
2007
1462
0.050
 Why?
Yeasts
1
2002
53
0.050
 Why?
Vaginosis, Bacterial
1
2001
12
0.050
 Why?
Women's Health
1
2004
364
0.050
 Why?
Cell Nucleus
1
2025
579
0.050
 Why?
Vaginal Diseases
1
2001
22
0.050
 Why?
Pregnancy
3
2016
6375
0.050
 Why?
Endometriosis
1
2001
50
0.050
 Why?
DNA, Neoplasm
2
1998
159
0.040
 Why?
DNA Primers
1
2002
510
0.040
 Why?
Vulvectomy
1
2020
2
0.040
 Why?
Epithelial Cells
1
2007
1036
0.040
 Why?
Histiocytoma, Malignant Fibrous
1
2020
4
0.040
 Why?
Dermatofibrosarcoma
1
2020
9
0.040
 Why?
Databases, Factual
2
2016
1279
0.040
 Why?
Hospitals, Urban
1
2001
134
0.040
 Why?
Clinical Trials, Phase I as Topic
1
2020
50
0.040
 Why?
DNA Repair
1
2022
205
0.040
 Why?
Medically Uninsured
1
2001
127
0.040
 Why?
Alleles
3
2017
845
0.040
 Why?
Liposarcoma
1
2020
27
0.040
 Why?
Anoikis
1
2020
32
0.040
 Why?
Prospective Studies
4
2016
7079
0.040
 Why?
Hemocyanins
1
2019
62
0.040
 Why?
Interleukin-10
1
2002
299
0.040
 Why?
DNA Damage
1
2022
364
0.040
 Why?
Diagnosis, Differential
2
2019
1417
0.040
 Why?
Chitinase-3-Like Protein 1
1
2019
19
0.040
 Why?
Rhabdomyosarcoma
1
2020
64
0.040
 Why?
Logistic Models
1
2004
1979
0.040
 Why?
Radiotherapy
1
2020
185
0.040
 Why?
SEER Program
1
2020
206
0.040
 Why?
Enzyme-Linked Immunosorbent Assay
1
2002
816
0.040
 Why?
Neoplasms, Cystic, Mucinous, and Serous
1
2019
25
0.040
 Why?
Intramolecular Oxidoreductases
1
2019
62
0.040
 Why?
Lymphatic Metastasis
1
2020
318
0.040
 Why?
Poly-ADP-Ribose Binding Proteins
1
2019
33
0.040
 Why?
DNA Polymerase II
1
2019
38
0.040
 Why?
Gene Knockdown Techniques
1
2020
312
0.040
 Why?
Chromosomes, Human, Pair 7
1
1998
15
0.040
 Why?
Cell Cycle Checkpoints
1
2019
95
0.040
 Why?
Cytoskeletal Proteins
1
2019
142
0.040
 Why?
Mechanistic Target of Rapamycin Complex 1
1
2019
115
0.040
 Why?
Mitosis
1
2019
178
0.040
 Why?
Microtubule-Associated Proteins
1
2019
190
0.040
 Why?
Europe
1
2019
362
0.040
 Why?
AMP-Activated Protein Kinases
1
2019
190
0.040
 Why?
Interleukin-6
1
2002
718
0.040
 Why?
Colorectal Neoplasms, Hereditary Nonpolyposis
1
1998
33
0.040
 Why?
Interleukin-1
1
2002
961
0.040
 Why?
Wnt Signaling Pathway
1
2019
166
0.040
 Why?
Image Cytometry
1
2017
7
0.040
 Why?
Chromosomes, Human, Pair 14
1
1997
19
0.030
 Why?
Ganciclovir
1
1996
51
0.030
 Why?
Chromosome Deletion
1
1997
102
0.030
 Why?
Socioeconomic Factors
1
2001
1209
0.030
 Why?
Hospitals, Private
1
2016
12
0.030
 Why?
Health Facility Size
1
2016
11
0.030
 Why?
Mass Spectrometry
1
2019
660
0.030
 Why?
Oxidation-Reduction
1
2020
1002
0.030
 Why?
Chorionic Gonadotropin
1
2016
80
0.030
 Why?
Time Factors
2
2019
6518
0.030
 Why?
Indoles
1
2019
372
0.030
 Why?
Ifosfamide
1
1996
34
0.030
 Why?
Cell Differentiation
2
2011
1901
0.030
 Why?
AC133 Antigen
1
2015
18
0.030
 Why?
Cell Separation
1
2017
313
0.030
 Why?
Cell Line, Transformed
1
1996
140
0.030
 Why?
Marriage
1
2017
113
0.030
 Why?
Tissue Array Analysis
1
2015
57
0.030
 Why?
Hospital Charges
1
1996
41
0.030
 Why?
Hospitals, Teaching
1
2016
111
0.030
 Why?
RNA-Binding Proteins
1
2019
388
0.030
 Why?
Caspase 3
1
2016
229
0.030
 Why?
Cystadenocarcinoma, Papillary
1
1995
5
0.030
 Why?
Carboplatin
1
1996
140
0.030
 Why?
Tumor Burden
1
2016
283
0.030
 Why?
Cell Cycle Proteins
1
2019
580
0.030
 Why?
Ataxia Telangiectasia Mutated Proteins
1
2015
64
0.030
 Why?
Disease Management
1
2019
593
0.030
 Why?
DNA Mismatch Repair
1
2015
47
0.030
 Why?
Ileus
1
2015
12
0.030
 Why?
Genes, p53
1
1995
70
0.030
 Why?
Income
1
2016
189
0.030
 Why?
Urinary Retention
1
2015
22
0.030
 Why?
Elective Surgical Procedures
1
2016
163
0.030
 Why?
Female Urogenital Diseases
1
2014
5
0.030
 Why?
RNA Interference
1
2016
441
0.030
 Why?
Taxoids
1
2015
95
0.030
 Why?
Antigens, Neoplasm
1
2017
310
0.030
 Why?
Morbidity
1
2015
302
0.030
 Why?
Intraoperative Complications
1
2015
132
0.030
 Why?
Sensitivity and Specificity
1
2019
1825
0.030
 Why?
Receptors, Androgen
1
2015
143
0.030
 Why?
Multivariate Analysis
2
1996
1496
0.030
 Why?
Drug Administration Schedule
1
2016
758
0.030
 Why?
Histones
1
2019
584
0.030
 Why?
Reference Values
1
1996
780
0.030
 Why?
Blood Volume
1
2014
60
0.030
 Why?
Point Mutation
1
1995
224
0.030
 Why?
Bleomycin
1
1996
240
0.030
 Why?
Bevacizumab
1
2015
131
0.030
 Why?
Infusions, Parenteral
1
2014
38
0.030
 Why?
Polyethyleneimine
1
2014
18
0.030
 Why?
Hemostatics
1
2014
46
0.030
 Why?
Pelvis
1
2015
102
0.030
 Why?
DNA, Viral
1
1996
348
0.030
 Why?
Deoxycytidine
1
2015
164
0.030
 Why?
Insurance, Health
1
2016
271
0.030
 Why?
Tumor Suppressor Proteins
1
2016
313
0.030
 Why?
Drainage
1
2014
165
0.030
 Why?
Receptors, Progesterone
1
2015
345
0.030
 Why?
Anemia
1
2015
161
0.030
 Why?
Preoperative Care
1
2015
342
0.030
 Why?
Lipids
1
2017
624
0.030
 Why?
Urban Population
1
2016
444
0.030
 Why?
Thrombocytopenia
1
2015
182
0.030
 Why?
Gene Transfer Techniques
1
2014
162
0.030
 Why?
Referral and Consultation
1
2018
732
0.030
 Why?
Polymorphism, Single-Stranded Conformational
3
1998
28
0.030
 Why?
Patient Readmission
1
2018
668
0.030
 Why?
Membrane Proteins
1
2019
1109
0.030
 Why?
Ultrasonography
1
2016
724
0.030
 Why?
Biomarkers
1
2024
3896
0.020
 Why?
Linear Models
1
1994
816
0.020
 Why?
Rural Population
1
2016
512
0.020
 Why?
Cholesterol
1
2014
406
0.020
 Why?
Zinc Finger E-box-Binding Homeobox 1
1
2011
22
0.020
 Why?
Perioperative Period
1
2011
48
0.020
 Why?
Analysis of Variance
1
1994
1271
0.020
 Why?
Protein Kinase Inhibitors
1
2017
872
0.020
 Why?
Mutant Proteins
1
2011
98
0.020
 Why?
Comorbidity
1
2016
1546
0.020
 Why?
DNA Fragmentation
1
2011
43
0.020
 Why?
Risk Reduction Behavior
1
2013
208
0.020
 Why?
Fas Ligand Protein
1
2011
59
0.020
 Why?
Hyperplasia
1
2011
170
0.020
 Why?
Tomography, X-Ray Computed
2
2014
2541
0.020
 Why?
Neovascularization, Pathologic
1
2012
291
0.020
 Why?
Neoplasm Transplantation
1
2011
258
0.020
 Why?
Administration, Oral
1
2012
759
0.020
 Why?
Polymorphism, Single Nucleotide
1
2017
2065
0.020
 Why?
Epithelial-Mesenchymal Transition
1
2011
199
0.020
 Why?
Antibodies, Monoclonal, Humanized
1
2015
764
0.020
 Why?
Pregnancy Complications
1
2014
491
0.020
 Why?
Anti-Bacterial Agents
2
2014
1671
0.020
 Why?
Regression Analysis
1
2011
984
0.020
 Why?
Polyethylene Glycols
1
2014
597
0.020
 Why?
Receptors, Urokinase Plasminogen Activator
1
2008
14
0.020
 Why?
Quality of Life
1
2020
2693
0.020
 Why?
Patient Discharge
1
2015
857
0.020
 Why?
Injections, Subcutaneous
1
2008
145
0.020
 Why?
Blotting, Western
1
2011
1169
0.020
 Why?
Placebos
1
2008
201
0.020
 Why?
Mice, Hairless
1
2008
61
0.020
 Why?
Enzyme Inhibitors
1
2011
811
0.020
 Why?
Sulfonamides
1
2011
500
0.020
 Why?
Quality Improvement
1
2015
1099
0.020
 Why?
Molecular Sequence Data
3
1996
2819
0.020
 Why?
Chromosome Mapping
2
1998
505
0.020
 Why?
Genetic Markers
2
1998
339
0.020
 Why?
Disease Models, Animal
1
2016
3953
0.020
 Why?
Receptors, Cell Surface
1
2008
371
0.020
 Why?
Frameshift Mutation
2
1996
31
0.020
 Why?
Cross-Sectional Studies
1
2017
5068
0.020
 Why?
Gene Deletion
2
1998
372
0.020
 Why?
Carcinosarcoma
1
2005
17
0.020
 Why?
Cohort Studies
1
2015
5407
0.010
 Why?
DNA Mutational Analysis
2
1996
386
0.010
 Why?
Colorado
1
2014
4394
0.010
 Why?
Severity of Illness Index
1
2011
2739
0.010
 Why?
Obesity
1
2016
2863
0.010
 Why?
Base Sequence
2
1996
2135
0.010
 Why?
Electrophoresis, Gel, Pulsed-Field
1
2001
19
0.010
 Why?
Metronidazole
1
2001
20
0.010
 Why?
Genes, rRNA
1
2001
41
0.010
 Why?
Microbial Sensitivity Tests
1
2001
336
0.010
 Why?
DNA, Bacterial
1
2001
324
0.010
 Why?
RNA, Ribosomal, 16S
1
2001
521
0.010
 Why?
Loss of Heterozygosity
1
1998
46
0.010
 Why?
Microsatellite Repeats
1
1998
162
0.010
 Why?
Actuarial Analysis
1
1996
25
0.010
 Why?
Ecosystem
1
2001
562
0.010
 Why?
Genes, Neoplasm
1
1995
20
0.010
 Why?
BRCA1 Protein
1
1995
65
0.010
 Why?
Sequence Analysis, DNA
1
1998
773
0.010
 Why?
Age of Onset
1
1996
494
0.010
 Why?
Introns
1
1995
249
0.010
 Why?
Exons
1
1995
338
0.010
 Why?
Amino Acid Sequence
1
1995
2041
0.010
 Why?
Male
1
2017
63194
0.010
 Why?
Behbakht's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
See all (451) concept(s)
_
Co-Authors Expand Description
See all (58) people
_
Similar People Expand Description
See all (60) people
_
Same Department Expand Description
Search Department
Physical Neighbors Expand Description
_

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)